NCT07019779 - Study of CM518D1 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

434

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

CM518D1

CM518D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.

BIOLOGICAL

CM518D1

CM518D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).

BIOLOGICAL

CM518D1

CM518D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.

Trial Locations (1)

Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou